Enjoy complimentary customisation on priority with our Enterprise License!
The hospital infection therapeutics market size is forecast to increase by USD 3.46 billion at a CAGR of 5.27% between 2023 and 2028. The growth of the market depends on several factors, including an increase in the incidence and prevalence of respiratory disorders, the growing geriatric population, and special drug designations. Market growth is significantly propelled by the rising incidence and prevalence of respiratory disorders, which remain a leading cause of mortality and disease burden globally, alongside other hospital infectious diseases. Conditions like chronic obstructive pulmonary disease (COPD), asthma, and acute respiratory infections are witnessing an uptick in prevalence. It also includes an in-depth analysis of market trends and analysis, market growth analysis and challenges. Furthermore, the report includes historic market data from 2018 - 2022.
To learn more about this report, View Report Sample
The market is pivotal in combating Healthcare-associated infections (HAIs) such as Central line-associated bloodstream infections, Catheter-associated urinary tract infections, and Ventilator-associated pneumonia. Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and urinary tract infections (UTIs) pose significant challenges, driving demand for innovative solutions. The Centers for Disease Control and Prevention (CDC) highlights antimicrobial resistance as a critical concern, necessitating effective therapeutics. However, constraints like high initial investment and reliability issues impede widespread adoption. Nonetheless, incentives for sustainable solutions, driven by environmental consciousness and cost reduction imperatives, offer opportunities. Industries like construction, automotive, and electronics prioritize product quality and sustainability, promoting eco-friendly, renewable solutions to curb carbon emissions. Leveraging economies of scale, the Market aims for sustainable, effective solutions amidst urbanization and environmental challenges. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increase in the incidence and prevalence of respiratory disorders is notably driving the market growth. Respiratory diseases are one of the main causes of mortality and disease burden worldwide, among other hospital infectious diseases. The prevalence of diseases such as chronic obstructive pulmonary disease (COPD), asthma, and acute respiratory infections is rising.
Respiratory diseases lead to more than four million deaths in developing countries. Pneumonia accounts for 18% of deaths among children under the age of five years. In the US, more than 534,242 deaths of men and women were due to chronic respiratory diseases. Hence, the rise in the incidence and prevalence of respiratory disorders will drive the growth of the global hospital infection therapeutics market during the forecast period.
The increasing hospital visits is a key trend influencing the market growth. The prevalence of chronic diseases is increasing worldwide, which is increasing the number of visits to hospitals. For instance, according to the CDC, in 2018, around 37,968 people received an HIV diagnosis in the US. In the same year, 7.9% of the patient population in the US stayed overnight in hospitals. Hospitals are a major source of infections, which results in a rise in morbidity and mortality in hospitalized patients.
The increasing incidence of hospital infectious diseases has created a significant social and economic burden on the healthcare system in countries such as the US and Australia. Moreover, the aging population is increasing globally, especially in countries such as Japan, the UK, the US, and Germany. This will increase the demand for blood culture tests performed on patients, which will support the growth of the hospital infection therapeutics market during the forecast period.
Stringent regulations may impede market growth. Vendors should adhere to stringent regulations enforced by regulatory authorities such as the US FDA and the EMA to obtain marketing approval for drugs. This can increase the R&D expenditure for drugs. The complicated regulatory process can adversely affect the development of drugs to treat hospital infectious diseases.
Only about one in every 5,000 new drugs reach the open market. The US FDA has also increased the regulatory surveillance of cancer drugs to avoid associated risks. Hence, a failure in drug performance can lead to a delay in receiving marketing approval. Thus, stringent regulations discourage new entrants as well as existing vendors from entering the market with novel therapeutic candidates. These factors will challenge global hospital infection therapeutics market growth during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abbott Laboratories - The company offers hospital infection therapeutics such as Favipiravir.
The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the antibiotics drugs segment will be significant during the forecast period. Antibiotics are therapeutic agents that are used for preventing and treating infections that are caused by bacteria and other susceptible microorganisms. The increasing prevalence of infectious diseases globally is driving the growth of the segment during the forecast period.
Get a glance at the market contribution of various segments View the PDF Sample
The antibiotics drugs segment was valued at USD 5.46 billion in 2018 and continued to grow by 2022. There are two types of antibiotics, namely broad-spectrum and narrow-spectrum antibiotics. Broad-spectrum antibiotics are effective against a wide range of microorganisms. They can be used in cases where bacteria do not respond to narrow-spectrum drugs. Some of the broad-spectrum antibiotics include amoxicillin, levofloxacin, gatifloxacin, streptomycin, tetracycline, and chloramphenicol. Narrow-spectrum antibiotics are active against a few certain groups of bacteria. Some of the narrow-spectrum antibiotics that are commonly used include azithromycin, clarithromycin, clindamycin, erythromycin, and vancomycin. Such factors will drive the growth of the antibiotic drug segment of the global market during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 33% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The growth of the market in the region is attributed to factors such as the increasing incidence of chronic diseases, growth in healthcare expenditure, and the rising preference for therapeutics over surgical procedures. Other factors, such as the growing focus of pharmaceutical and biotechnology companies on R&D, the increasing geriatric population, and the presence of global and regional vendors, are also driving the regional market during the forecast period.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The market is witnessing significant growth, driven by the increasing prevalence of healthcare-associated infections (HAIs) such as central line-associated bloodstream infections, catheter-associated urinary tract infections (CAUTI), and ventilator-associated pneumonia. Challenges posed by antimicrobial resistance, particularly from pathogens like Methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii, further underscore the urgent need for effective therapeutics. Start-ups, universities, and research institutes like the Indian Institute of Science Education and Research (IISER) and the Central Drug Research Institute (CSIR-CDRI) are actively involved in developing innovative solutions. Regulatory bodies such as the US Food and Drug Administration (FDA) play a crucial role in ensuring the safety and efficacy of these therapeutics. Sustainability and environmental consciousness are driving forces, with a focus on eco-friendly and renewable solutions amidst global sustainability challenges. However, constraints like high initial investment and supply chain disruptions pose challenges to market growth. Technological advancements, coupled with incentives and increased demand, are expected to shape the future trajectory of the Market.
Moreover, the market is witnessing a surge in demand due to the escalating threat of nosocomially acquired infections, such as Catheter-Associated Urinary Tract Infection (CAUTI) and Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Key players like Innoviva Specialty Therapeutics are innovating solutions to combat acute uncomplicated cystitis and other healthcare-associated infections. The market landscape depends on Growth Drivers and Restraints, Intermittency and reliability issues, Growing demand, Environmental awareness, Hospital Infection Therapeutics solutions, Performance, Production growth rate, Volume, Storage facilities. Growth drivers include a growing awareness of environmental impacts and the need for cost reduction in healthcare settings. However, challenges such as infrastructure limitations and policy uncertainty pose restraints to market expansion. Influencers like digital technologies and materials play a crucial role in enhancing the efficiency and effectiveness of hospital infection therapeutics. Additionally, industries like construction, automotive, and electronics contribute to the demand for high-quality products, driving production growth rates and volumes in this sector. Measures to address intermittency, reliability, and grid upgrades are imperative, alongside efforts to reduce carbon emissions and reliance on fossil fuels and nuclear energy. Shortages of critical materials further underscore the importance of sustainable solutions in this market segment.
Market Scope |
|
Report Coverage |
Details |
Page number |
184 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.27% |
Market growth 2024-2028 |
USD 3.46 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.91 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 33% |
Key countries |
US, Germany, China, France, and UK |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, AbbVie Inc., Achilles Therapeutics plc, AstraZeneca Plc, Basilea Pharmaceutica Ltd., Bayer AG, Bristol Myers Squibb Co., Cipla Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Spero Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.